CML-395 Efficacy and Safety Results From ASCEMBL, a Phase III Study of Asciminib vs. Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): Week 96 Update
- Réa, D.
- Hochhaus, A.
- Mauro, M.J.
- Minami, Y.
- Lomaia, E.
- Voloshin, S.
- Turkina, A.
- Kim, D.-W.
- Apperley, J.F.
- Cortes, J.E.
- Abdo, A.
- Fogliatto, L.M.
- Kim, D.D.H.
- Coutre, P.L.
- Saussele, S.
- Annunziata, M.
- Hughes, T.P.
- Chaudhri, N.
- Chee, L.
- García-Gutiérrez, V.
- Sasaki, K.
- Kapoor, S.
- Allepuz, A.
- Quenet, S.
- Bédoucha, V.
- Boquimpani, C.
- Mostrar todos os autores +
ISSN: 2152-2669, 2152-2650
Ano de publicación: 2022
Volume: 22
Páxinas: S295-S296
Tipo: Artigo